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See Article, pages 446–457More than 500 million people worldwide are chroni-
cally infected with the hepatitis B (HBV) or hepatitis C
virus (HCV). Infections with these viruses are the lead-
ing cause of chronic hepatitis, liver cirrhosis and hepato-
cellular carcinoma (HCC). As a consequence, major
research eﬀorts have been devoted to HBV and HCV.
However, relatively little is known about interactions
between HBV and HCV in patients co-infected with
both viruses.
Co-infection with HBV and HCV is common due to
shared modes of transmission (reviewed in [1,2]). Avail-
able evidence indicates more frequent development of
cirrhosis and an increased incidence of HCC in HBV/
HCV co-infection as compared to monoinfection by
either virus. As a result, studies have reported an excess
liver-related mortality in HBV/HCV co-infection as
compared to HBV or HCV infection alone [3].
While liver disease activity and ﬁbrosis progression
are generally more severe in the presence of double
infection, an inverse relationship in the replicative levels
of the two viruses has been noted, suggesting direct or
indirect viral interference [1,2]. Challenging this notion,
longitudinal studies revealed that the two viruses may
replicate independently from each other in some
patients, with ﬂuctuations in the serum level of one virus
that appear unrelated to the viremia of the other [4].
However, suppression of HBV replication was found0168-8278/$36.00  2009 European Association for the Study of the Liver.
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acute hepatitis C and, conversely, inhibition of HCV
replication has been observed in patients with chronic
hepatitis C superinfected with HBV [5,6]. Finally,
HBV reactivation was observed in co-infected patients
after successful treatment of HCV with pegylated inter-
feron-a (PEG-IFN-a) and ribavirin [7,8]. Therefore,
while liver disease appears to be enhanced, the two
viruses seem to inhibit each other at the replicative level.
From the basic perspective, HBV/HCV co-infection
implies the exciting scenario of two pathogens with com-
pletely divergent life cycles meeting in the same host.
HBV belongs to a family of hepatotropic DNA viruses
(Hepadnaviridae) (reviewed in [9]). The viral genome
consists of an incompletely double-stranded circular
DNA of about 3.2-kbp length. The viral RNAs are tran-
scribed in the nucleus from the covalently closed circular
DNA template. Replication occurs within nucleocapsids
via the reverse transcription of packaged pregenomic
RNA.
HCV is classiﬁed in the Hepacivirus genus within the
Flaviviridae family. It contains a 9.6-kb positive-strand
RNA genome that encodes a polyprotein precursor of
about 3000 amino acids (reviewed in [10]). The polypro-
tein precursor is co- and posttranslationally processed
by cellular and viral proteases to yield the mature struc-
tural and nonstructural proteins. HCV replication takes
place in a cytoplasmic membrane-associated complex
(membranous web).
Interactions between HBV and HCV have been diﬃ-
cult to study because of the lack of appropriate model
systems. Indeed, robust infection of cultured cells by
HBV remains a challenge, with only few cell types, includ-
ing HepaRG and primary human or tupaia hepatocytesPublished by Elsevier B.V. All rights reserved.
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appear to be susceptible to eﬃcient HCV infection and
replication (George Koutsoudakis and Ralf Bartensch-
lager, personal communication) and primary human as
well as tupaia cells support only low level HCV replica-
tion [14,15]. Therefore, the few studies that have
addressed interactions between HBV and HCV were
based on heterologous overexpression of viral proteins
and have yielded conﬂicting results. For example, some
studies demonstrated that HCV core inhibits HBV rep-
lication [16,17] while others did not [18]. Similarly, HCV
NS5A was found to enhance [19] or inhibit [20] HBV
replication. Thus, it remains unclear whether there is a
direct interference between HBV and HCV.
Against this background, the study by Eyre et al.
published in this issue of the Journal provides important
new insights into HBV/HCV co-infection [21]. The
authors used Huh-7 human HCC cells to study interac-
tions between HBV and HCV. Huh-7 cells support HBV
replication and virion formation as well as the entire
HCV life cycle, including viral entry, RNA replication,
and infectious particle release [22–25]. As these cells can-
not be infected by HBV, the authors used a recombinant
adenovirus vector (AdHBV) to intracellularly deliver a
replication-competent HBV genome. A recombinant
adenovirus expressing the green ﬂuorescent protein
(AdGFP) served as control for nonspeciﬁc eﬀects.
Huh-7 cells were also infected with cell culture-derived
HCV (HCVcc) [23–25]. Importantly, HCV replication
and virion production were not aﬀected when cells were
co-infected simultaneously with AdHBV and HCVcc or
when HCVcc-infected cells were subsequently exposed
to the recombinant adenovirus. For unknown reasons,
HCV RNA replication was even increased when the cells
were preinfected with AdHBV. On the other hand, HBV
DNA levels in cells and supernatants were either unaf-
fected or slightly increased by HCVcc infection. Thus,
in this replicating context, there appeared to be no or
only a minor inﬂuence of HBV on HCV and vice versa.
The key ﬁndings of this study are in line with a recent
study by Bellecave et al. [26]. In this study, Huh-7 cells
were engineered to inducibly replicate and produce
infectious HBV using a tetracycline-regulated gene
expression system. HCV was introduced into these sta-
ble cell lines as well as into control Huh-7 cells inducibly
expressing the GFP either in the form of selectable HCV
replicons or HCVcc. In this highly reproducible model
system, HBV and HCV were found to replicate in the
same cell without overt interference. In addition, speciﬁc
inhibition of one virus did not aﬀect the replication and
gene expression of the other. Finally, cells harboring
replicating HBV could be infected by HCVcc, arguing
against superinfection exclusion, and they also sup-
ported eﬃcient production of infectious HCV.
Taken together, the studies by Eyre et al. and Belle-
cave et al. reveal the absence of direct interferencebetween HBV and HCV in vitro. This remarkable obser-
vation indicates that – at least in Huh-7 cells – the two
viruses rely on distinct and non-competing sets of host
factors for their replication. At the same time, these
results suggest that the viral interference observed in
co-infected patients is likely due to indirect mechanisms
mediated by innate and/or adaptive host immune
responses. In this context, both HBV and HCV replica-
tion are susceptible to antiviral cytokines, including type
I and type II IFNs as well as tumor necrosis factor-a,
that are produced by the infected cell or inﬁltrating T-
cells [27,28]. An alternative explanation for the viral
interference observed in vivo may relate to host factors
that become limiting in human hepatocytes in the liver
but not in Huh-7 cells in vitro. Clearly, the development
of in vitro and in vivo model systems that will allow to
study the eﬀect of innate and adaptive responses in
HBV/HCV co-infection as well as the establishment of
experimental conditions that more closely resemble
human hepatocytes or the naturally infected liver repre-
sents the next challenge.
In conclusion, the study by Eyre et al. appearing in
this issue of the Journal [21] and the study by Bellecave
et al. published earlier this year [26] demonstrate that
HBV and HCV can replicate in the same cell without
evidence for direct interference in vitro. Therefore, the
viral interference observed in co-infected patients is
probably due to indirect mechanisms mediated by innate
and/or adaptive host immune responses. These ﬁndings
provide new insights into the pathogenesis of HBV/
HCV co-infection and may contribute to its clinical
management in the future.Acknowledgments
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